Well, they did produce statistically significant results in terms of reducing the number of hospitalization days by 6 days (patients emerging alive). Also, their mortality data with critically ill patients was really good (24% reduction on small sample size though - 62). No one has showed such numbers. Head of FDA has repeatedly said that she won’t care about p value (or statistically significant value) as long as it’s clinically significant with saving lives of these covid patients. And now because it’s a small biotech and not one of the big pharmas such as Gilead, Pfizer, J&J, etc. they wouldn’t grant EUA and rather ask them to run another 140 critical patients before granting EUA. This way, big pharmas catch up? In the interim, let the critical covid patients die every day? We still have over 700 people dying every day in the US. There’s no drug that has demonstrated such results with critical patients so far. Safety profile is excellent. The same drug has been studied and have succeeded in HIV ph 3 trial. In totally, they have safety data from over 2000 patients in all the ph 2/3 trials CYDY have run. What’s missing other than they don’t have the credibility and deep pockets of big pharmas?